



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

# Deficiency in the nuclear long noncoding RNA causes myogenic defects and heart remodeling in mice

### Citation for published version:

Ballarino, M, Cipriano, A, Tita, R, Santini, T, Desideri, F, Morlando, M, Colantoni, A, Carrieri, C, Nicoletti, C, Musarò, A, Carroll, DO & Bozzoni, I 2018, 'Deficiency in the nuclear long noncoding RNA causes myogenic defects and heart remodeling in mice', *EMBO Journal*, vol. 37, no. 18.  
<https://doi.org/10.15252/embj.201899697>

### Digital Object Identifier (DOI):

[10.15252/embj.201899697](https://doi.org/10.15252/embj.201899697)

### Link:

[Link to publication record in Edinburgh Research Explorer](#)

### Document Version:

Publisher's PDF, also known as Version of record

### Published In:

EMBO Journal

### Publisher Rights Statement:

This is an open access article under the terms of the Creative Commons Attribution Non Commercial-NoDerivs 4.0 License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made.

### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.



### Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



SOURCE  
DATATRANSPARENT  
PROCESSOPEN  
ACCESS

# Deficiency in the nuclear long noncoding RNA *Charme* causes myogenic defects and heart remodeling in mice

Monica Ballarino<sup>1,†</sup>, Andrea Cipriano<sup>1,†</sup>, Rossella Tita<sup>1,†</sup>, Tiziana Santini<sup>2</sup>, Fabio Desideri<sup>1</sup>, Mariangela Morlando<sup>1</sup>, Alessio Colantoni<sup>1</sup>, Claudia Carrieri<sup>3</sup>, Carmine Nicoletti<sup>4</sup>, Antonio Musarò<sup>2,4</sup>, Dónal O' Carroll<sup>3</sup>  & Irene Bozzoni<sup>1,2,5,6,\*</sup> 

## Abstract

Myogenesis is a highly regulated process that involves the conversion of progenitor cells into multinucleated myofibers. Besides proteins and miRNAs, long noncoding RNAs (lncRNAs) have been shown to participate in myogenic regulatory circuitries. Here, we characterize a murine chromatin-associated muscle-specific lncRNA, *Charme*, which contributes to the robustness of the myogenic program *in vitro* and *in vivo*. In myocytes, *Charme* depletion triggers the disassembly of a specific chromosomal domain and the downregulation of myogenic genes contained therein. Notably, several *Charme*-sensitive genes are associated with human cardiomyopathies and *Charme* depletion in mice results in a peculiar cardiac remodeling phenotype with changes in size, structure, and shape of the heart. Moreover, the existence of an orthologous transcript in human, regulating the same subset of target genes, suggests an important and evolutionarily conserved function for *Charme*. Altogether, these data describe a new example of a chromatin-associated lncRNA regulating the robustness of skeletal and cardiac myogenesis.

**Keywords** CRISPR/Cas9; epigenetic control; heart development; lncRNAs; myogenesis

**Subject Categories** Chromatin, Epigenetics, Genomics & Functional Genomics; RNA Biology; Vascular Biology & Angiogenesis

**DOI** 10.15252/embj.201899697 | Received 23 April 2018 | Revised 17 July 2018 | Accepted 21 July 2018 | Published online 3 September 2018

**The EMBO Journal (2018) 37: e99697**

## Introduction

Myogenesis is a highly regulated multistep process, in which the conversion of progenitor cells into multinucleated and functional myofibers can be easily reproduced *in vitro*. Besides the well-characterized protein factors and miRNAs (Buckingham & Rigby, 2014), also long noncoding RNAs (lncRNAs) have been shown to participate in myogenic regulatory circuitries (Rinn & Chang, 2012; Fatica & Bozzoni, 2014; Ballarino *et al.*, 2015). lncRNAs, through their ability to interact with nucleic acids as well as with proteins (Guttman & Rinn, 2012; Rinn & Chang, 2012; Batista & Chang, 2013; Cipriano & Ballarino, 2018), act as scaffolds for the formation of specific functional complexes where different proteins and RNA and even DNA molecules can be tethered together (Wutz *et al.*, 2002; Clemson *et al.*, 2009; Tsai *et al.*, 2010; Ariel *et al.*, 2014; Hacisuleyman *et al.*, 2014; Ribeiro *et al.*, 2017). Nuclear lncRNAs have been described to control the transcriptional myogenic program through diverse modes of action (Ballarino *et al.*, 2016): as enhancer-associated transcripts (Mousavi *et al.*, 2014; Mueller *et al.*, 2015; Ounzain *et al.*, 2015), as guides for the recruitment of PRCs and MLL epigenetic regulators or DNA methyltransferases (DNMT; Wang *et al.*, 2015, 2016), and also as allosteric inhibitors (Han *et al.*, 2014; Wang *et al.*, 2016). Important functions have also been ascribed to cytoplasmic lncRNAs through their ability to control mRNA stability and translation (Wang *et al.*, 2013), to modulate miRNA function acting as competing endogenous RNA (Cesana *et al.*, 2011; Salmena *et al.*, 2011; Han *et al.*, 2015), or to encode for micropeptides (Anderson *et al.*, 2015; Nelson *et al.*, 2016). Interestingly, de-regulation of these molecules was often associated with skeletal (Ballarino *et al.*, 2015) and cardiac (Han *et al.*, 2014; Ounzain & Pedrazzini, 2015; Uchida & Dimmeler, 2015; Wang *et al.*, 2016) diseases.

<sup>1</sup> Department of Biology and Biotechnology Charles Darwin, Sapienza University of Rome, Rome, Italy

<sup>2</sup> Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Rome, Italy

<sup>3</sup> MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK

<sup>4</sup> DAHFMU-Unit of Histology and Medical Embryology, Sapienza University of Rome, Rome, Italy

<sup>5</sup> Institute Pasteur Fondazione Cenci-Bolognietti, Sapienza University of Rome, Rome, Italy

<sup>6</sup> Institute of Molecular Biology and Pathology, CNR, Sapienza University of Rome, Rome, Italy

\*Corresponding author. Tel: +39 06 4991 2202; Fax: +39 06 4991 2500; E-mail: irene.bozzoni@uniroma1.it

<sup>†</sup>These authors contributed equally to this work

We recently identified a novel nuclear lncRNA, *Charme* (Chromatin architect of muscle expression), conserved in human and with restricted expression in skeletal and cardiac muscles (Ballarino *et al*, 2015). Here, we show that the depletion of *Charme* produces the downregulation of myogenic genes, many of which involved in human cardiomyopathies (Becker *et al*, 2011; Harvey & Leinwand, 2011). Through a combination of ChIRP and FISH approaches, we identified a *Charme*/chromatin interaction that is required for the correct expression of a subset of relevant myogenic genes. Notably, the functional knockout of *Charme* in mice produced morphological alterations of both skeletal and cardiac muscles and resulted in a shorter life span. The structural and functional conservation of *Charme* in human further corroborates its relevance in the control of proper muscle differentiation and homeostasis.

## Results

### *Charme* is a chromatin-associated long noncoding RNA

Previous transcriptome analysis from murine C<sub>2</sub>C<sub>12</sub> myoblasts and myotubes discovered novel lncRNAs with muscle restricted expression (Ballarino *et al*, 2015). Among them, lnc-405, here named *Charme* (Chromatin architect of muscle expression; Figs 1A and EV1A), is a novel isoform of the 5430431A17Rik transcript of particular interest for (i) its specific expression in both skeletal and cardiac muscles, (ii) its predominant nuclear localization, and (iii) the presence of an orthologue transcript in human.

The expression of *Charme* was studied by 5'-RACE, Northern blot, and RT-PCR analyses (Figs 1B and EV1B): It is predominantly localized in the nucleus, mainly associated with the chromatin, with a minor fraction being present in the cytoplasm. In C<sub>2</sub>C<sub>12</sub> cells, RNA FISH showed a well-defined punctate localization of *Charme* in the nuclei of myofibers defined as multinucleated cells expressing the myogenic marker myosin heavy chain (MHC). *Charme* was instead absent in proliferating myoblasts, identified as mononucleated cells lacking MHC staining (Fig 1C). *Charme* expression starts at day 1 upon shift to differentiation medium (DM), reaching high levels at day 3 (Fig 1D). In agreement with RNA-seq data, RT-PCR analyses revealed the existence of an isoform (*pCharme*) still retaining intron 1 and devoid of intron 2 (Figs 1A and D, and EV1C and D). Notably, actinomycin experiments indicated that this isoform was as stable

as the fully spliced *Charme* species (*mCharme*; Fig EV1E). RNA FISH with intron probes detected an average of three nuclear spots which co-localize with the exonic signals (Appendix Fig S1A and B). This pattern, whose specificity was tested by both RNaseA and RNAi sensitivity (Appendix Fig S1C), well correlates with the aneuploidy of C<sub>2</sub>C<sub>12</sub> cells having three copies of chromosome 7, where *Charme* locus resides. The number, the intensity, and the focal plane distribution of the signals obtained with exonic vs. intronic probes allowed us to establish that the major fraction of *Charme* is retained at the sites of its own transcription as a precursor species.

### *Charme* depletion affects myogenesis

To analyze the role of *Charme* in myogenesis, we treated C<sub>2</sub>C<sub>12</sub> myotubes with two different LNA GAPmers (GAP-2 and GAP-2/3; Fig 1A), which provided 60–70% average reduction in both intron 1-harboring (*pCharme*) and mature (*mCharme*) *Charme* transcripts (Fig 1E). Upon knockdown, 50% decrease of the mRNAs for two diagnostic markers of differentiation, myosin creatine kinase (*MCK*) and the myosin heavy chain (*MHC*), was found (Fig 1E and Table EV1) indicating quite a clear impairment of myogenesis. Morphological parameters were also specifically affected: a consistent reduction in the caliber of differentiated MHC-positive myotubes (Fig 1F) was observed, together with a decrease of more than twofold of the fusion index (F.I.) and of the number of nuclei per fiber (Nu/MT). In parallel, the number of mononucleated (MonoMHC<sup>+</sup>) cells increased by a factor of 3 (Fig 1G). These results suggest that *Charme* inhibition mainly affects the ability of myogenic cells to fuse and to proceed to later stages of differentiation.

RNA-seq analysis on cells treated with GAP-2 or GAP-2/3, in parallel with a scramble control (Appendix Fig S2A and B) led to the identification of a set of 826 genes differentially expressed upon *Charme* depletion with two different sets of LNA GAPmers (Fig 2A and Appendix Fig S2C). Of these, 302 were upregulated and 524 downregulated in comparison with the scramble condition (Fig 2A and Table EV1). Real-time quantitative PCR on a selected number of targets confirmed the sequencing data (Appendix Fig S2D). The Gene Ontology (GO) term enrichment study performed with the FIDEA web tool (D'Andrea *et al*, 2013) suggested that *Charme* may act by activating genes involved in muscle function and contraction

**Figure 1. *Charme* is a novel long noncoding transcript associated with myogenesis.**

- Genomic structure of the *Charme* locus. The position of PCR primers, LNA GAPmers (GAP-2, GAP-2/3), and *in situ* probes (green—intronic; or red—exonic) used in this study are shown together with the produced *Charme* isoforms.
- Semiquantitative RT-PCR (sqRT-PCR) quantification of *pCharme* and *mCharme* in cytoplasmic (Cyt), nuclear (Nu), nucleoplasmic (Np), or chromatin (Chr) fractions from 2-day differentiated myotubes. The quality of fractionation was tested with mature (*GAPDH*) and precursor (*pre-GAPDH*) RNAs.
- Co-staining of MHC protein (green) and *Charme* RNA (red) in fully differentiated myotubes. DAPI, 4',6-diamidino-2-phenylindole. MHC, myosin heavy chain. Scale bar = 10  $\mu$ m.
- sqRT-PCR quantification of *Charme* amplicons in growth (GM) and differentiated (DM) conditions. *GAPDH* mRNA serves as control. —, RT-minus control.
- Real-time RT-PCR (qRT-PCR) quantification of *mCharme* and *pCharme*, *MCK*, and *MHC* in differentiated myotubes treated with GAP-2, GAP-2/3, or GAP-scr as negative control. Data were normalized to *GAPDH* mRNA and represent mean  $\pm$  SD of triplicates.
- Immunofluorescence staining for MHC on C<sub>2</sub>C<sub>12</sub> cells treated with GAP-scr, GAP-2, or GAP-2/3 (right) and merged with the DAPI staining (left). Scale bar = 100  $\mu$ m.
- Quantification of myotubes formation (F.I., Nu/MT, MonoMHC<sup>+</sup>) on cells treated with GAP-2, GAP-2/3, or GAP-scr. Bars represent mean  $\pm$  SD of triplicates of randomly chosen microscope fields.

Data information: \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, paired Student's *t*-test.

Source data are available online for this figure.




Figure 1.




Figure 2.



**Figure 2. *Charme* regulates myogenesis by interacting with the *nctc* region.**

- A RNA-seq analysis of transcriptome changes upon *Charme* depletion. Heatmap was drawn using the heatmap3 R package and represents hierarchical clustering of the common genes differentially expressed upon *Charme* depletion with both GAP-2 and GAP-2/3 GAPmers, compared to GAP-scr control. The expression levels correspond to mean-centered log<sub>2</sub>-transformed FPKM values. See also Table EV1.
- B Gene Ontology (GO) term enrichment analyses performed by FIDEA (D'Andrea et al, 2013) on genes downregulated (top) or upregulated (bottom) upon *Charme* depletion. Bars indicate the top 10 categories of cellular components in decreasing order of significance. Threshold (*P*-value < 0.01) is indicated by the dashed black line.
- C KEGG pathway enrichment analysis on genes downregulated by *Charme* depletion.
- D Quantification of recovered RNA (left) and DNA (right) upon *Charme* ChIRP with the pool of biotinylated probes reported in Table EV4.
- E RNA/DNA FISH for *Charme* RNA and *nctc* (left) or *Inc-31* (right) loci in 2-day differentiated myotubes. Inserts show a magnification of the spots converted into binary images (I), 3D rendering (II), or rotated on Z-axis (III). Yellow arrows indicate signals overlapping. Right histogram reports the mean  $\pm$  SD percentage of nuclei with paired or overlapped spots from two biological replicates. Scale bar = 5  $\mu$ m.
- F qRT-PCR quantification of *Charme* and *Charme* target genes in GAP-scr- vs. GAP-2-transfected (2-day differentiated) myotubes. PCR data were normalized to *GAPDH* and represent mean  $\pm$  SD of triplicates.
- G RNA Pol II (left) and H3K9ac (right) ChIP performed in GAP-scr- vs. GAP-2-transfected myotubes. The recovered chromatin was analyzed by qPCR in parallel with an intergenic region used to normalize the two (GAP-scr vs. GAP-2) conditions. Data were subtracted for background and are expressed as input percentage (% Input). Histograms represent the mean  $\pm$  SEM of three biological replicates.

Data information: \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, unpaired Student's *t*-test.

Source data are available online for this figure.

processes (Fig 2B). To note, we did not observe significant enrichment of any cell-cycle- and/or proliferation-related categories.

Interestingly, *Charme* depletion resulted in the downregulation of genes (i.e., *Myh7* and *Tnnt2*; Appendix Fig S2E) implicated in several types of cardiomyopathies (Fig 2C), such as familial hypertrophic (HCM), dilated (DCM), and arrhythmogenic right ventricular (ARVC) cardiomyopathies (Harvey & Leinwand, 2011; Becker et al, 2011; Maron et al, 2012).

### ***pCharme* is localized at specific chromosomal sites**

To elucidate *Charme* mode of action, we proceeded with the identification of the sites of chromatin interaction in C<sub>2</sub>C<sub>12</sub> cells. Chromatin isolation by RNA purification (ChIRP) analysis was carried out with two different pools of four alternating antisense biotinylated oligonucleotides (even and odd), together with four oligonucleotides against lacZ sequences (Appendix Fig S2F). Figure 2D (panel RNA) shows that a specific pull-down of *pCharme* isoform was obtained when compared to the lacZ control and the *GAPDH* pre-mRNA, while no enrichment was obtained for *mCharme* isoform. The co-purified DNA was subjected to high-throughput sequencing (ChIRP-seq), and the reads from odd and even pull-downs were compared to those of the lacZ control (Table EV2). In agreement with the strong chromatin association, the major peak corresponded to the *Charme* locus. Several other genomic loci were identified (Table EV2); among them, the most prominent corresponded to a region (hereafter named as *nctc*) located on the same *Charme* chromosome (chr7:149,746,850–149,747,033) and containing several genes affected by *Charme* depletion (Appendix Fig S2G and Table EV1). The *nctc* peak was validated by PCR amplification on the initial ChIRP samples (Fig 2D, panel DNA) and reproduced in independent replicates. Interestingly, this region contains a shared core muscle enhancer (CME; Alzhanov et al, 2010) required for muscle-specific activation of *Igf2* and *H19* (Eun et al, 2013), which are both decreased upon *Charme* knockdown (Table EV1). Interestingly, the knockout of part of this enhancer was previously shown to produce the loss of *Igf2* expression and defects in muscle differentiation (Kaffer et al, 2001). Therefore, for subsequent analysis we concentrated on this specific locus.

The physical association of *pCharme* RNA with *nctc* (98 Mb far from *Charme* locus) was validated by FISH analysis with probes against *Charme* RNA (red) and BAC probes against the target loci (green). A detailed quantification of the signals indicated that in more than 60% of the nuclei *Charme* is in close proximity with the *nctc* region, with 2/3 of the signals showing partial overlapping (Fig 2E). No proximity was instead found when the unrelated *Inc-31* locus (Ballarino et al, 2015), which was absent in the ChIRP-seq dataset, was used as negative control (Fig 2E).

Notably, the surrounding 2.5 Mb of the ChIRP peak in the *nctc* region contains relevant myogenic genes, such as *Igf2*, *Tnnt3*, and *Tnni2*, that were downregulated upon *Charme* depletion in the RNA-seq dataset (Tables EV1 and EV2). qRT-PCR confirmed their downregulation upon *Charme* depletion both at the mRNA and pre-mRNA levels (Fig 2F). Along this line, ChIP analyses performed in conditions of *Charme* downregulation showed a strong decrease in the association of the RNA polymerase II (RNA Pol II) and in the acetylation of lysine K9 histone 3 (H3K9ac) of these genes (Fig 2G). Altogether, these data indicate that the effect of *Charme* on these target genes is exerted at the transcriptional level.

Due to the strong accumulation of *pCharme* at the sites of its own transcription, we tested whether the *Charme* genomic locus itself could be in contact with *nctc*. To this purpose, FISH analyses were performed with DNA BAC probes flanking the *Charme* gene (red) or overlapping the *nctc* region (green; Figs 3 and EV2A–C). In GM conditions, when *Charme* is not expressed, the two districts are clearly distinguished as independent spots (Fig 3A, left panel, and Fig EV2C, GM). Notably, upon *Charme* expression, the two regions get close (Fig EV2C, DM1 and DM1.5, and Fig EV2D) with a consistent percentage of chromosomes showing overlapping or proximal signals at days 1 and 1.5 of differentiation (Fig 3A, right panels, and Fig EV2C). As control, no proximity was found with the unrelated *Inc-31* locus (Figs 3A and EV2C, lower panels). Notably, the *pCharme*-mediated long-range interaction was significantly reduced when *Charme* was downregulated by 50% through GAP-2 treatment (Figs 3B and EV2E). Overall, these *in vitro* data suggest an important role of *pCharme* in a long-range physical interaction between two chromatin districts distantly located, but present on the same chromosome.




Figure 3.

**Figure 3. *pCharme* contributes to the maintenance of chromatin contacts with the *nctc* region.**

- A Double DNA FISH for *Charme* and *nctc* (top) or *Charme* and *Inc-31* (bottom) loci in growth (GM) and differentiated (DM1) conditions. Histograms represent the percentages  $\pm$  SD of chromosome 7 showing paired and overlapped signals in GM, DM1, and DM1.5 days of differentiation from two biological replicates.
- B DNA/DNA FISH for *Charme* and *nctc* loci in GAP-scr- vs. GAP-2-transfected myotubes (DM1). Percentage of *Charme* locus  $\pm$  SD from three biological replicates showing paired and overlapped signals with *nctc* is indicated in the histograms below.

Data information: \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , unpaired Student's *t*-test. Scale bar = 5  $\mu$ m.

Source data are available online for this figure.

A further evidence for *Charme* acting in the nucleus at the sites of its own transcription derives from experiments where we tried to rescue the phenotype of *Charme* depletion with a cDNA construct expressing a GAPmer-resistant *mCharme*. This construct failed to recover the expression of myogenic markers (Fig EV2F) and produced a transcript with a cytoplasmic-restricted localization (Fig EV2G). The lack of rescue with cytoplasmic RNA further supports the finding that the active *Charme* species is the nuclear one; moreover, these results are in line with the accepted notion that for chromatin-associated lncRNAs acting in *cis*, rescue phenotypes are not obtained with exogenous gene overexpression (Goff & Rinn, 2015; Wang et al, 2015).

### ***Charme* functional knockout in mice affects the myogenic process**

In consideration of the interesting function of *Charme* observed *in vitro*, the study of its function *in vivo* was strongly demanded. Therefore, the CRISPR/Cas9 methodology was used to generate a *Charme* null allele in mice. In order to avoid any structural alteration of the locus, we inserted at the beginning of exon 2 the strong poly(A) polyadenylation signal of the  $\beta$ -globin gene (Levitt et al, 1989) followed by two MAZ sites, known to promote efficient cleavage and transcriptional termination (Yonaha & Proudfoot, 2000; Gromak et al, 2006; Fig 4A). The correct genomic editing was confirmed in a founder mouse, and the *Charme* null allele was backcrossed for four generations to obtain homozygous animals (Fig EV3A). *Charme*<sup>-/-</sup> mice are viable, fertile, and produced in Mendelian ratios. Analysis of skeletal muscles of 1-month-old mutant and control animals indicated that the insertion of the poly(A)/MAZ cassette resulted in a very effective depletion of both *pCharme* and *mCharme* isoforms (Fig 4B). The histological analysis of skeletal muscles from *Charme*<sup>-/-</sup> mice revealed a slight but significant reduction in the area of the fiber sections (Fig 4C), which is the most common parameter used to assess correct tissue morphology. Moreover, as a further evidence for delayed differentiation, a significant decrease in the mRNAs of myogenic markers myosin creatine kinase (*MCK*) and myosin heavy chain (*MHC*) was observed (Fig 4D). These features appeared consistent with the reduction in the fiber caliber of differentiating myotubes and the decrease in myoblast fusion observed *in vitro* in C<sub>2</sub>C<sub>12</sub> cells (Fig 1G). Moreover, the *Charme* targets located in the *nctc* region identified in C<sub>2</sub>C<sub>12</sub> cells were also specifically affected in murine muscle tissues (Fig 4E).

### ***Charme*<sup>-/-</sup> mice exhibit an altered cardiac phenotype**


Since *Charme* also displays a cardiac restricted expression (Ballarino et al, 2015), we analyzed the effects of *Charme* knockout in heart. A peculiar phenotype was detected when analyzing the heart of *Charme*<sup>-/-</sup> mice where the expression of both

*pCharme* and *mCharme* isoforms was almost abolished by the poly(A) site insertion (Fig 5A). Morphometric analyses, performed with hematoxylin/eosin staining in both adult (Fig 5B) and neonatal (Fig EV3B) cardiac sections, showed in all the mice tested an increase in the heart area (Ha), a definite decrease in ventricular chamber dimensions (LVa and RVa), and an increase in the thickness of the ventricular free walls (LVw and RVw) and interventricular septum (IVS; Fig EV3C). Moreover, as expected from this altered morphology, higher blood pressures (DBP and SBP) and heart-to-body weight ratio (Hw/Bw) were also detected in *Charme*<sup>-/-</sup> animals (Fig EV3D). Notably, compared to wild-type littermates, which have a life expectancy of 24–38 months, none of the available *Charme*<sup>-/-</sup> mice ( $n = 5$ ,  $P < 0.001$ ) survived for more than 1 year, suggesting a midlife lethality caused by *Charme* ablation. In analogy to skeletal muscles, the histological analysis performed on *Charme*<sup>-/-</sup> cardiac tissues revealed a reduction in cell area (Fig 5C) together with the downregulation of terminal differentiation markers (Fig 5D). To note, the expression of *Igf2*, the only gene of the *nctc* region expressed in the cardiac tissue, was also found to be downregulated. Notably, in line with the *in vitro* data, DNA/DNA FISH experiments performed in neonatal hearts proved that the co-localization between *Charme* and the *nctc* regions is also occurring *in vivo* while it is impaired in *Charme*<sup>-/-</sup> animals (Fig 5E). Interestingly, the proximity was also found to persist in adult hearts (Fig EV3E).

### **Identification of a functionally conserved human *Charme* transcript**

An evolutionary conservation analysis performed by examining RNA-seq (Legnini et al, 2017) and FANTOM5 (Noguchi et al, 2017) data revealed the existence of a *Charme* orthologue transcript (*hs-Charme*) produced by the human syntenic locus (Fig EV4A), with a structure very similar to the murine counterpart (Figs 6A and EV4B–D, and Table EV3). Notably, the *hs-Charme* locus displays an overall ~45% sequence identity (Fig EV4E and Appendix Table S1), which is a high value for a lncRNA genomic region (Pang et al, 2006). Similarly to the murine counterpart (Ballarino et al, 2015), the expression of the early myogenic transcriptional factor MyoD was found to precede that of *hs-Charme* (Fig EV5A, left panel; and Table EV3) and a specific peak of MyoD ChIP-seq (MacQuarrie et al, 2013) was identified, as in mouse, at the level of MyoD canonical E-boxes upstream to the TSS (Fig EV5B and C). Altogether, these data suggest a common regulatory control of MyoD on mouse and human *Charme* RNA expression. Indeed, both *hs-pCharme* and *hs-mCharme* were found expressed in human primary myoblasts upon induction of differentiation; moreover, both transcripts resulted in delayed expression in myoblasts from Duchenne muscular dystrophy patients (Figs 6B and EV5A, right panel; and Table EV3), where MyoD expression is strongly impaired and cells are blocked in a more





**Figure 4. Generation and skeletal muscle characterization of *Charme*<sup>-/-</sup> mice.**

**A** Top: *Charme* locus is shown together with the position of sgRNA1 and sgRNA2 divergent single guides. Bottom: design of the single-stranded oligodeoxynucleotide (ssODN) containing the two homology arms (gray line) and the 100-nt-long poly(A)/2xMAZ cassette.

**B** qRT-PCR quantification of *mCharme* and *pCharme* expression in skeletal homogenates from *Charme*<sup>+/+</sup> and *Charme*<sup>-/-</sup> mice. The number of mice tested is the same for the two groups, and it is indicated in the white bars. Data were normalized to *GAPDH* mRNA and represent mean ± SEM.

**C** Dystrophin staining analyzed by immunofluorescence on *Charme*<sup>+/+</sup> and *Charme*<sup>-/-</sup> skeletal (gastrocnemius) biopsies. The mean ± SD of cross-sectional area (μm<sup>2</sup>) is reported in the histograms besides. In total, *N* = 667 and 1,039 fibers per condition were analyzed. Original magnification = ×10. The number of mice tested is the same for the two groups, and it is indicated in the white bars. Scale bar = 100 μm.

**D** qRT-PCR quantification of *MHC* and *MCK* transcripts in skeletal (gastrocnemius) homogenates from *Charme*<sup>+/+</sup> and *Charme*<sup>-/-</sup> mice. The number of mice tested is the same for the two groups, and it is indicated in the white bars. Data were normalized to *GAPDH* mRNA and represent mean ± SEM.

**E** qRT-PCR quantification of *Tnnt3*, *Tnni2*, and *Igf2* transcripts in skeletal (gastrocnemius) homogenates from *Charme*<sup>+/+</sup> and *Charme*<sup>-/-</sup> mice. Data were normalized to *GAPDH* mRNA and represent mean ± SEM. The number of mice tested is the same for the two groups, and it is indicated in the white bars.

Data information: \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, unpaired Student's *t*-test.

Source data are available online for this figure.




Figure 5.

**Figure 5. *Charme*<sup>-/-</sup> mice exhibit an altered cardiac phenotype.**

- A qRT-PCR quantification of *mCharme* and *pCharme* expression in cardiac homogenates from *Charme*<sup>+/+</sup> and *Charme*<sup>-/-</sup> mice. The number of mice tested (the same for the two groups) is indicated in the white bars. Data were normalized to *GAPDH* mRNA and represent mean  $\pm$  SEM.
- B Hematoxylin and eosin staining of transverse sections of the myocardium in 1-month-old *Charme*<sup>+/+</sup> (left) and *Charme*<sup>-/-</sup> (right) mice. Left (LV) and right (RV) ventricles are indicated. Scale bar = 1 mm.
- C Dystrophin staining analyzed by immunofluorescence on *Charme*<sup>+/+</sup> and *Charme*<sup>-/-</sup> cardiac tissues. The mean  $\pm$  SD of cross-sectional area ( $\mu\text{m}^2$ ) is reported in the histograms besides. In total,  $N = 1,491$  and  $1,724$  fibers per condition were analyzed. Original magnification =  $\times 20$ . The number of mice tested is the same for the two groups, and it is indicated in the white bars. Scale bar =  $100\ \mu\text{m}$ .
- D qRT-PCR quantification of *Myh7*, *Tnnt2*, and *Igf2* transcripts in cardiac homogenates from 1-month-old *Charme*<sup>+/+</sup> and *Charme*<sup>-/-</sup> mice. Data were normalized to *GAPDH* mRNA and represent mean  $\pm$  SEM. The number of mice tested (the same for the two groups) is indicated in the white bars.
- E DNA/DNA FISH for *Charme* and *nctc* loci in *Charme*<sup>+/+</sup> and *Charme*<sup>-/-</sup> neonatal (1 day old) cardiac tissues are shown. Percentage of *Charme* locus  $\pm$  SD showing paired and overlapped signals with *nctc* is indicated in the histogram.  $N = 395$  and  $315$  chromosome pairs per condition were analyzed. Scale bar =  $5\ \mu\text{m}$ .

Data information: \* $P < 0.05$ , \*\*\* $P < 0.001$ , unpaired Student's *t*-test.

Source data are available online for this figure.

proliferative state (Delaporte *et al*, 1984; Cazzella *et al*, 2012). Similarly to the murine species, *hs-pCharme* is mainly accumulated in the nucleus as an unprocessed species still containing intron 1 while the fully spliced isoform (*hs-mCharme*) is mainly localized in the cytoplasm compartment (Fig 6C and D). In human primary myoblasts, GAPmer-directed knockdown produced a strong downregulation of both *hs-pCharme* and *hs-mCharme* transcripts as well as the myogenic markers identified in mouse (Fig 6E). Altogether, these data suggest a conserved role of *Charme* in mammalian myogenesis.

## Discussion

In this study, we show the characterization of *Charme*, a chromatin-associated lncRNA induced upon myogenic differentiation. *In vitro* *Charme* knockdown causes defects in myoblast fusion and downregulation of several crucial myogenic genes. Among them, several have been previously shown to be involved in familial hypertrophic (HCM), dilated (DCM), and arrhythmogenic right ventricular (ARVC) cardiomyopathies (Maron *et al*, 2012). Interestingly, an orthologue transcript, *hs-Charme*, was identified in human myoblasts. Similarly to its murine counterpart, *hs-Charme* is induced upon differentiation, and its depletion affects the same subset of myogenic genes. These data support the notion of an important conserved function of *Charme* in mammalian myogenesis.

Through ChIRP analyses, we found that *Charme* associates with several different genomic loci containing a number of the myogenic genes affected by its depletion. One of these regions, *nctc*, seemed

particularly interesting because it is localized in *cis* with respect to the *Charme* locus and harbors a shared core muscle enhancer (CME; Alzhanov *et al*, 2010), previously shown to control muscle-specific activation of the neighboring *Igf2* and *H19* promoters (Eun *et al*, 2013). Moreover, the knockout of part of the *nctc* region was performed by several groups and resulted in the loss of *Igf2* expression and in defective myogenesis (Kaffer *et al*, 2001; Alzhanov & Rotwein, 2016). The *nctc* region also contains genes involved in muscle activity and metabolism, such as muscle troponins (*Tnni2* and *Tnni3*). Interestingly, all these genes are affected by *Charme* depletion, indicating a direct connection between the lncRNA expression and the muscle-specific transcriptional output of the region. We also show that *Charme*, retained at the sites of its own transcription as an incompletely spliced form, is required for the maintenance of the long-distance chromosomal interaction with the *nctc* locus and for consolidating the expression of the myogenic genes therein included. These data are in line with recent studies indicating the importance of the tridimensional chromatin folding and with the evidence that the eukaryotic genome is organized in a hierarchy of well-defined, highly compartmentalized, and extremely dynamic structures within the nucleus, where chromosome territories are segmented into functional compartments (Rowley & Corces, 2016). These regions can be considered as discrete regulatory units where genes far apart in terms of linear distance but close in space are activated or repressed in a coordinated fashion during cell differentiation (Zaug & Cech, 1980; Guerrier-Takada *et al*, 1983).

Notably, *Charme* depletion *in vivo* produced similar molecular and morphological phenotypes as the one observed *in vitro*. In fact,

**Figure 6. Expression profiling and characterization of the human *Charme* upon *in vitro* differentiation of primary myoblasts.**

- A The human *Charme* genomic locus is indicated together with the position of PCR primers (*hs-2*, *hs-3*) and LNA GAPmers (*hs-GAP-int1*, *hs-GAP-ex2*) used in this study.
- B RT-PCR quantification of the human *hs-pCharme* (upper panel) and *hs-mCharme* (lower panel) in control healthy or dystrophic (DMD) primary myoblasts in proliferating (GM) and differentiating (3, 6, 10) conditions. Data were normalized to *GAPDH* mRNA and represent mean  $\pm$  SD. Three biological replicates were analyzed.
- C sqRT-PCR quantification of *hs-pCharme* and *hs-mCharme* in cytoplasmic (Cyt) and nuclear (Nu) RNA fractions from differentiated myotubes. The quality of fractionation was tested with precursor (*pre-GAPDH*) and mature (*GAPDH*) RNAs.
- D Analysis by PCR amplification of *hs-pCharme* intron 1 retention. The position of the oligos used for the analyses is depicted aside.
- E qRT-PCR quantification of *hs-mCharme*, *hs-pCharme*, *MCK*, *MHC*, *Igf2*, *Tnnt3*, *Tnni2*, and *Dmd* mRNAs in primary cells treated with *hs-GAP-int1*, *hs-GAP-ex2*, or *hs-GAP-scr* GAPmers at day 5 of differentiation. PCR data were normalized to *GAPDH* mRNA and represent mean  $\pm$  SD of duplicates.
- F Proposed model for *pCharme* mode of action: In proliferating myoblasts, *Charme* is not expressed and its chromatin locus is spatially distant from the *nctc* region; in differentiated myotubes, *pCharme* stabilizes the physical proximity of the two loci allowing their co-regulated expression.

Data information: \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , unpaired Student's *t*-test.

Source data are available online for this figure.




Figure 6.

the same genes affected in C<sub>2</sub>C<sub>12</sub> cells were downregulated in the skeletal muscles of *Charme*<sup>-/-</sup> mice and the decrease in fiber calibers observed in adult muscles correlated well with the reduction in the caliber of differentiating myotubes observed *in vitro*. *Charme*<sup>-/-</sup> mice showed also a clear cardiac phenotype, characterized by a conspicuous decrease in fiber size, and resulting in an overall heart remodeling and alteration of morphological and functional parameters. Also in this district, *Charme* was shown to contribute to the physical proximity with the *nctc* genomic region and to affect the cardiac expression of Igf2. Since *Charme* depletion provides a clear heart phenotype already at neonatal stages, the observed remodeling of the cardiac tissue must represent outcomes of defects starting early during embryonic development and persisting in adult life. The reduction in life span observed in adult mice indicated the persistence of effects of *Charme* depletion even at very advanced ages. It is important to note that this is the first time that such a cardiac phenotype has been directly ascribed to a lncRNA ablation in the absence of any stressful condition (Guttman *et al*, 2010; Devaux *et al*, 2015). Moreover, the chronic *in vivo* phenotype, where the overall alteration of tissue homeostasis and cardiac structure leads to late lethality, correlates well with the role of *Charme* as a fine-tuning regulator.

Since *Charme* is interacting with several other regions besides the *nctc* locus, it is important to underline that these other domains will likely contribute to the overall phenotype observed *in vitro* and *in vivo*. For the *nctc* locus, which has been prioritized in this study, a clear correlation between the expression of the myogenic genes therein included and *Charme* activity has been assessed (Fig 6F). Further characterization of the other *Charme* targets will be necessary to complete the genome-wide clarification of its function in skeletal and cardiac muscles.

## Materials and Methods

### Cell culture conditions and transfection

C<sub>2</sub>C<sub>12</sub> murine myoblasts were cultured as previously described (Agostini *et al*, 2013) and differentiated in 0.5% fetal bovine serum (FBS). Human control healthy and DMD myoblasts from the Telethon Neuromuscular Biobank were cultured as previously described (Faghihi *et al*, 2008) and differentiated with human skeletal muscle differentiation medium (PromoCell). RNAi experiments were performed with 75 nM of LNA GAPmers (Exiqon) using Lipofectamine 2000 (Invitrogen). GAPmers were designed against *Charme* exon 2 (GAP-2) or EX2/EX3 splice junction (GAP-2/3) sequences using the Exiqon web tool. Sequences are reported in Table EV4.

### RNA analyses

Total RNA from myoblasts/myotubes was isolated using QIAzol Lysis Reagent (Qiagen)/chloroform extraction followed by spin-column purification (RNeasy Mini Kit; Qiagen) and quantification by NanoDrop (Thermo Scientific). Northern blot analysis was performed on 12 µg of total RNA from mouse myoblasts/myotubes. Total RNA was denatured in glyoxal loading dye (Ambion) for 30 min at 50°C and loaded on 1.2% agarose gel. Electrophoresis

was carried out for 2 h at 60 V. RNA was transferred overnight on Hybond-N+ membrane (GE Healthcare) by capillarity in 10× SSC. The transferred RNA was UV-cross-linked (1,200 × 100 µJ/cm<sup>2</sup>), and the membrane was washed in 50 mM Tris (pH 8) for 20 min at 45°C. Pre-hybridization and hybridization were performed in NorthernMax buffer (Ambion) at 68°C (30 min and overnight, respectively). For the hybridization, 500 ng of DIG-labeled probes (DIG-RNA Labeling Mix; Roche) was produced by *in vitro* transcription with T7 RNA polymerase (Promega) using a PCR-amplified *Charme* template (see Table EV4 for oligo sequences). The membrane was washed twice in 2× SSC/0.1% SDS and twice in 0.2× SSC/0.1% SDS at 68°C. The membrane was finally processed for DIG detection using the DIG Luminescence Detection Kit (Roche), according to the manufacturer's instructions. Nucleoplasm/chromatin/cytoplasmic fractionation was performed using the NE-PER Kit (Pierce-Thermo Scientific) following the manufacturer's specifications. 5'-RACE was performed using FirstChoice RLM-RACE kit (Ambion) on 5 µg of total RNA and by PCR amplification with *Charme* 4 and *Charme* 3 reverse primers. For semiquantitative and quantitative PCR analyses, RNA (0.5–1.0 µg) was reverse-transcribed using SuperScript III RT (Life Technologies) according to the manufacturer's instructions and amplified by PCR using MyTaq (Bioline) enzyme. Real-Time PCRs (qPCRs) were performed using QuantiTect SYBR Green (Qiagen).

### RNA-seq and functional enrichment analysis

RNA-seq data were analyzed using RAP (D'Antonio *et al*, 2015) using FASTQC (www.bioinformatics.babraham.ac.uk), NGS QC Toolkit (Patel & Jain, 2012), Bowtie 2 (Langmead & Salzberg, 2012), TopHat2 (Kim *et al*, 2013), and Cufflinks and Cuffdiff (Trapnell *et al*, 2012, 2013). Default parameters were used for the analyses except for library type (fr-firststrand), mate inner distance (set to 30), standard deviation of inner distance (set to 60), and minimum read length (set to 30). Reads were aligned using mm9 assembly. Genes deregulated in both GAP-2 and GAP-2/3 conditions were selected choosing Cuffdiff *q*-value < 0.1, abs(log<sub>2</sub> fold change) > 0.5, and variation of gene expression in the same direction. Functional enrichment analysis was performed by FIDEA (D'Andrea *et al*, 2013) using the genes expressed in the scramble condition as background.

RNA-seq data from GSE70389 (Legnini *et al*, 2017) were analyzed as described above. The read coverage and the Cufflinks tracks were loaded on IGV genome browser (Robinson *et al*, 2011; Thorvaldsdóttir *et al*, 2013); see also Fig EV4B.

### Chromatin isolation by RNA purification (ChIRP) sequencing

ChIRP-seq was performed according to the procedure described by Chang (Chu *et al*, 2011) using nuclear extract from 10<sup>7</sup> differentiated myotubes/each sample. *Charme* pull-down was performed with different sets of oligos (Appendix Fig S2F) or lacZ as control. Input and purified DNA were sequenced with HiSeq 2500 (40 million single-end, 50-base pair-long reads/sample). Reads were pre-processed with Trimmomatic (Bolger *et al*, 2014) and Cutadapt (Martin, 2011) to trim the 5' and 3' adapters and to remove the first five nucleotides, whose average quality score was lower than that of the other nucleotides. Low-complexity reads were then removed



using the DUST algorithm included in the PRINSEQ suite (Fatica & Bozzoni, 2014; Morlando *et al*, 2014; complexity score threshold = 7). The procedure adopted by Chu and colleagues (Chu *et al*, 2011) was used to find the EVEN and ODD common peaks (mm9 assembly, MACS14 bw = 300 (Zhang *et al*, 2008), fold enrichment/input > 2, average coverage > 10, and Pearson correlation > 0.3). BEDTools (Quinlan & Hall, 2010) was used to identify the overlapping lacZ peaks (obtained with MACS14 using the input as background). Peaks with fold enrichment/input 25 times lower than that of the overlapping lacZ peaks and with more than 50% of the length covered by repeats (Chen, 2002; <http://www.repeatmasker.org>) were excluded. HOMER (Heinz *et al*, 2010) was employed to annotate peaks using GENCODE M4 (Harrow *et al*, 2012). WindowBed tool was used to find all downregulated genes which are closer than 2.5 Mb to *Charme* ChIRP peaks.

### Immunofluorescence and DNA/RNA FISH

MHC staining and dystrophin staining were performed as previously described (Cazzella *et al*, 2012). Samples were imaged on inverted microscope Zeiss AxioObserver A1 equipped with AxioCam MRm R camera and Plan-Neofluar EC 10 × /0.3 M27 and LD 20 × /0.4 Korr objectives. Images were acquired with AxioVision Rel.4.8 software.

Fluorescent *in situ* hybridization (FISH) was carried out on cells that adhered to collagen (Corning) using fluorescent (Fluorescein or Cy3)-conjugated nick-translated BAC DNA (DNA FISH) or synthetic DNA oligonucleotides (RNA FISH). Three-dimensional (3D) DNA FISH on C<sub>2</sub>C<sub>12</sub> was performed with some modifications of an already described procedure (Cremer *et al*, 2008). Briefly, cells were fixed in 4% PFA (20 min at 4°C) and pre-processed by freeze-thawing permeabilization to ensure the preservation of nuclear structures. After denaturation, FISH probes were hybridized O.N. at 37°C and samples washed, DAPI-stained, and mounted in ProLong Diamond reagent (Thermo Fisher Scientific). For DNA FISH on histological muscle sections, after permeabilization with Triton buffer (0.5% Triton X-100/PBS), a mild pepsin digestion (pepsin 0.1%/0.1 M HCl) was applied before denaturation in order to reduce the autofluorescence deriving from protein components. For RNA FISH, fixed cells were permeabilized in 0.5% Triton (10 min at 4°C) and incubated O.N. at 37°C with fluorescent DNA probes diluted in hybridization buffer (10% dextran sulfate, 2× SSC, 10% formamide, 2 mM ribonucleoside-vanadyl complex). The specificity of RNA FISH was tested by pre-incubating the cells with 200 µg/ml RNaseA for 1 h at 37°C, or by GAPmer transfection. Sequential hybridizations were used for DNA/RNA FISH. Samples were imaged on inverted microscope (Olympus IX73) equipped with a Confocal Imager (CREST X-LIGHT) spinning disk, a Coolsnap MYO CCD camera (Photometrics), and a Lumencor Spectra X LED illumination. Images were acquired with 60× NA1.35 oil objective (UPLAN-SApo) and MetaMorph (Molecular Devices) using 300 (Cy3), 500 (Fluorescein), or 100 (DAPI) ms as exposure time.

### Immunofluorescence and RNA and DNA FISH post-acquisition analyses

The fusion index (F.I.) indicates the percentage of nuclei in multinucleated myotubes (defined by at least two nuclei) divided by total

number of nuclei in a microscope field; the average number of nuclei inside individual myotubes (Nu/MT) was determined by dividing the total number of nuclei by the number of myotubes; and the fraction of mononucleated MHC-positive cells (MonoMHC+) was calculated as the mean percentage of nuclei in MHC-positive cells divided by total number of nuclei in each field. The number of nuclei was estimated by the average of nuclei counted in three independent and randomly chosen microscope fields. Dystrophin staining was used to evidence the border of the muscle fibers. The single-channel dystrophin images were merged in dystrophin/DAPI images with ImageJ software and then used to quantify the fiber number manually. The fiber cross-sectional area analysis was performed on dystrophin immunofluorescence by using a semi-automatic tool (Briguet *et al*, 2004; Mula *et al*, 2013). The immunofluorescence images were binarized to obtain a mask of fiber boundaries and then applied to originals for the automatic measure of the areas. Statistical analysis of fiber cross-sectional area (CSA) was performed using unpaired *t*-test, and the differences between means were considered significant at  $P \leq 0.05$ .

For DNA/RNA FISH staining analysis, the Z-stack confocal microscopy images were taken automatically (0.2-µm path) and merged with maximum-intensity projection or processed for image analysis. A Laplacian-of-Gaussian filter was applied to 3D volume after image acquisition to enhance the spots signal over background (Raj *et al*, 2008). Intensity threshold was manually adjusted using MetaMorph or ImageJ software. Signal from cells hybridized without probes was considered as background.

Spatial proximity analysis of long-split, paired, or overlapped patterns in DNA FISH was performed by computing the 3D interallelic distance on Z-stack acquisitions using ImageJ (Spot Distance; Schober *et al*, 2008). Changes in the C<sub>2</sub>C<sub>12</sub> (elliptic) shape of nuclei occurring along differentiation were taken into account as in Cremer *et al* (1984) before the calculation of the Normalized Distances mean (ND; ND = Interallelic Distances/ $d$ ,  $d$  = major axis + minor axis/2). Values above or below the paired ND range were attributed to long-split or overlapped patterns, respectively (Fig EV2A). The co-planarity and the co-localization of the DNA and RNA spots were established by recording the main grayscale value (expressed as arbitrary units) along Z-planes using ImageJ (Plot Z-axis profile). A Gaussian function (determination coefficient > 0.9) was used to fit the fluorescent intensities and to extrapolate the main Z-plane value, which corresponds to the maximum fluorescence value of green and red channels in DNA FISH staining (Fig EV2B). The percentage of nuclei showing spatial proximity of genomic loci was calculated by manual screening on binarized images on a total of about 500 nuclei showing at least one pair of spots with paired or overlapped patterns. To determine spot intensity (fluorescence intensity) in RNA FISH analysis, we measured the mean gray value of nonbinarized images within a selection that circumscribes the spot; this value was divided by the diameter of the spot ( $d = 2 \cdot ((3/4 \cdot V)/\pi)^{1/3}$ ) by applying the formula of a sphere with the same volume of the spot.

### Chromatin immunoprecipitation (ChIP)

ChIP experiments were performed on chromatin extracts according to the manufacturer's protocol (MAGnify ChIP; Life Technologies) by O.N. incubation with 2 µg of immobilized monoclonal anti-RNA

Pol II (Millipore), anti-acetyl-histone H3 (Lys9; Millipore), or rabbit IgG antibodies. A standard curve was generated for each primer pair testing 5-point dilutions of input sample. Fold enrichment was quantified using qRT-PCR (SYBR Green; Qiagen) and calculated as a percentage of input chromatin (% Inp). Data from GAP-scr vs. GAP-2 conditions were normalized to an unrelated genomic region and represent the mean of three experiments  $\pm$  SEM.

### Generation of *Charme*<sup>-/-</sup> mice

*Charme*<sup>-/-</sup> mice were generated in the C57BL/6 background using a CRISPR genome-editing system (Yang *et al.*, 2014). A pair of divergent single guide RNAs (sgRNAs) inside exon 2 was designed using the <http://crisp.mit.edu> resource and cloned into the pX330 vector (Addgene). The sgRNAs were amplified together with the T7 promoter to generate templates for *in vitro* transcription. For homologous recombination, a ssODN (200 nt) containing two homology arms (50 nt each), a short poly(A) site (49 nt), and two MAZ sites (Levitt *et al.*, 1989; Yonaha & Proudfoot, 2000) was synthesized by IDT. *In vitro* transcribed Cas9 mRNA and sgRNAs were injected into the cytoplasm of fertilized eggs of C57BL/6 mice in M2 medium (Sigma-Aldrich, MO, USA). Successful knockout was validated by PCR analyses (see Table EV4 for oligo sequences). The wild-type allele yielded an amplicon of 235 bp, whereas the mutated allele yielded an amplicon of 335 bp. One mouse was selected to mate with the wild-type C57BL/6 strain to obtain F1-generation mice. Heterozygous F1 offspring were interbred to establish the *Charme*<sup>-/-</sup> strain. Molecular and histological analyses were assessed in F4-generation mice.

### Offspring genotyping

DNA extraction from tail biopsies was performed using RBC Real Genomics DNA Extraction Kit (RBC Bioscience) according to the manufacturer's protocol. The poly(A)/MAZ insertion was detected by PCR amplifications with oligo pairs int1b-3 (Table EV4).

### Histological analysis

Mice were sacrificed at different ages, and the morphological changes in the skeletal and cardiac muscles were observed under light microscopy. Muscle tissues were fixed in 4% formaldehyde, and sections were stained with hematoxylin and eosin.

### Study approval

Animals were treated in respect of housing, nutrition, and care according to the guidelines of Good Laboratory Practice (GLP). MB and RT have successfully completed the Module1 as co-coordinated by the Administration of Animal Facilities in the premises of EMBL. The EMBL course meets the requirements of European legislation on basic training of researchers.

## Data availability

Data that support the findings of this study have been deposited in GEO with the primary accession code GSE94498 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94498>).

**Expanded View** for this article is available online.

## Acknowledgements

The authors acknowledge O. Sthandier and M. Marchioni for technical support, L. Bisceglie for support in ChIRP analysis, and the EuroBioBank and Telethon Network of Genetic Biobanks (GTB12001F) for providing biological samples. This work was partially supported by grants from ERC-2013 (AdG 340172–MUNCODD), Telethon (GGP16213), Human Frontiers Science Program Award RGP0009/2014, Parent Project Italia, AFM-Telethon (17835), Epigen-Epigenomics Flagship Project, and AriSLA full grant 2014 “ARCI” to I.B.; Telethon GGP14066 to A.M.; Fondazione Roma to I.B. and A.M.; ERC grant agreement no. GA 310206 (FP7/2007-2013) to D.O'C.; and Sapienza University (prot. RM11715C7C8176C1) to M.B.

## Author contributions

IB conceived the study, wrote the manuscript, and secured funding; MB designed the study, wrote the manuscript, and conducted ChIRP and ChIP analyses; ACi performed most of the experiments and the computational analysis of RNA-seq; CC and DO'C developed the *Charme*<sup>-/-</sup> FO mice; RT generated and characterized the *Charme*<sup>-/-</sup> mice; TS conducted the RNA and DNA FISH experiments; FD performed the Northern blot analyses; ACo performed the computational analysis of ChIRP-seq; MM provided expertise on myogenic field; and CN and AM provided expertise and feedback on the experiments in mice.

## Conflict of interest

The authors declare that they have no conflict of interest.

## References

- Agostini F, Zanzoni A, Klus P, Marchese D, Cirillo D, Tartaglia GG (2013) catRAPID omics: a web server for large-scale prediction of protein-RNA interactions. *Bioinformatics* 29: 2928–2930
- Alzhanov DT, McInerney SF, Rotwein P (2010) Long range interactions regulate Igf2 gene transcription during skeletal muscle differentiation. *J Biol Chem* 285: 38969–38977
- Alzhanov D, Rotwein P (2016) Characterizing a distal muscle enhancer in the mouse Igf2 locus. *Physiol Genomics* 48: 167–172
- Anderson DM, Anderson KM, Chang C-L, Makarewich CA, Nelson BR, McAnally JR, Kasaragod P, Shelton JM, Liou J, Bassel-Duby R, Olson EN (2015) A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. *Cell* 160: 595–606
- Ariel F, Jegu T, Latrasse D, Romero-Barrios N, Christ A, Benhamed M, Crespi M (2014) Noncoding transcription by alternative RNA polymerases dynamically regulates an auxin-driven chromatin loop. *Mol Cell* 55: 383–396
- Ballarino M, Cazzella V, D'Andrea D, Grassi L, Bisceglie L, Cipriano A, Santini T, Pinnarò C, Morlando M, Tramontano A, Bozzoni I (2015) Novel long noncoding RNAs (lncRNAs) in myogenesis: a miR-31 overlapping lncRNA transcript controls myoblast differentiation. *Mol Cell Biol* 35: 728–736
- Ballarino M, Morlando M, Fatica A, Bozzoni I (2016) Non-coding RNAs in muscle differentiation and musculoskeletal disease. *J Clin Invest* 126: 2021–2030
- Batista PJ, Chang HY (2013) Long noncoding RNAs: cellular address codes in development and disease. *Cell* 152: 1298–1307
- Becker JR, Deo RC, Werdich AA, Panàková D, Coy S, MacRae CA (2011) Human cardiomyopathy mutations induce myocyte hyperplasia and activate

- hypertrophic pathways during cardiogenesis in zebrafish. *Dis Model Mech* 4: 400–410
- Bolger AM, Lohse M, Usadel B (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30: 2114–2120
- Briguet A, Courdier-Fruh I, Foster M, Meier T, Magyar JP (2004) Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. *Neuromuscul Disord* 14: 675–682
- Buckingham M, Rigby PWJ (2014) Gene regulatory networks and transcriptional mechanisms that control myogenesis. *Dev Cell* 28: 225–238
- Cazzella V, Martone J, Pinnarò C, Santini T, Twayana SS, Sthandier O, D'Amico A, Ricotti V, Bertini E, Muntoni F, Bozzoni I (2012) Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts. *Mol Ther* 20: 2134–2142
- Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I (2011) A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. *Cell* 147: 358–369
- Chen N (2002) *Using RepeatMasker to identify repetitive elements in genomic sequences*. Hoboken, NJ: John Wiley & Sons Inc
- Chu C, Qu K, Zhong FL, Artandi SE, Chang HY (2011) Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. *Mol Cell* 44: 667–678
- Cipriano A, Ballarino M (2018) The ever-evolving concept of the gene: the use of RNA/protein experimental techniques to understand genome functions. *Front Mol Biosci* 5: 2928
- Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A, Lawrence JB (2009) An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. *Mol Cell* 33: 717–726
- Cremer T, Baumann H, Nakanishi K, Cremer C (1984) Correlation between interphase and metaphase chromosome arrangements as studied by laser-UV-microbeam experiments. In *Chromosomes today*, Bennett MD, Gropp A, Wolf U (eds), pp 203–212. Dordrecht, the Netherlands: Springer
- Cremer M, Grasser F, Lanctôt C, Müller S, Neusser M, Zinner R, Solovei I, Cremer T (2008) Multicolor 3D fluorescence *in situ* hybridization for imaging interphase chromosomes. *Methods Mol Biol* 463: 205–239
- D'Andrea D, Grassi L, Mazzapoda M, Tramontano A (2013) FIDEA: a server for the functional interpretation of differential expression analysis. *Nucleic Acids Res* 41: W84–W88
- D'Antonio M, De Meo PD, Pallocca M, Picardi E, D'Erchia AM, Calogero RA, Castrignanò T, Pesole G (2015) RAP: RNA-Seq analysis pipeline, a new cloud-based NGS web application. *BMC Genom* 16: S3
- Delaporte C, Dehaupas M, Fardeau M (1984) Comparison between the growth pattern of cell cultures from normal and Duchenne dystrophy muscle. *J Neurol Sci* 64: 149–160
- Devaux Y, Zangrando J, Schroen B, Creemers EE, Pedrazzini T, Chang C-P, Dorn GW, Thum T, Heymans S, Cardiolinc Network (2015) Long noncoding RNAs in cardiac development and ageing. *Nat Rev Cardiol* 12: 415–425
- Eun B, Sampley ML, Van Winkle MT, Good AL, Kachman MM, Pfeifer K (2013) The Igf2/H19 muscle enhancer is an active transcriptional complex. *Nucleic Acids Res* 41: 8126–8134
- Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, Finch CE, St Laurent GIII, Kenny PJ, Wahlestedt C (2008) Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of  $\beta$ -secretase. *Nat Med* 14: 723–730
- Fatica A, Bozzoni I (2014) Long non-coding RNAs: new players in cell differentiation and development. *Nat Rev Genet* 15: 7–21
- Goff LA, Rinn JL (2015) Linking RNA biology to lncRNAs. *Genome Res* 25: 1456–1465
- Gromak N, West S, Proudfoot NJ (2006) Pause sites promote transcriptional termination of mammalian RNA polymerase II. *Mol Cell Biol* 26: 3986–3996
- Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altman S (1983) The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. *Cell* 35: 849–857
- Guttman M, Garber M, Levin JZ, Donaghey J, Robinson J, Adiconis X, Fan L, Koziol MJ, Gnirke A, Nusbaum C, Rinn JL, Lander ES, Regev A (2010) *Ab initio* reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. *Nat Biotechnol* 28: 503–510
- Guttman M, Rinn JL (2012) Modular regulatory principles of large non-coding RNAs. *Nature* 482: 339–346
- Hacisuleyman E, Goff LA, Trapnell C, Williams A, Henao-Mejia J, Sun L, McClanahan P, Hendrickson DG, Sauvageau M, Kelley DR, Morse M, Engreitz J, Lander ES, Guttman M, Lodish HF, Flavell R, Raj A, Rinn JL (2014) Topological organization of multichromosomal regions by the long intergenic noncoding RNA Firre. *Nat Struct Mol Biol* 21: 198–206
- Han P, Li W, Lin C-H, Yang J, Shang C, Nurnberg ST, Jin KK, Xu W, Lin C-Y, Lin C-J, Xiong Y, Chien H-C, Zhou B, Ashley E, Bernstein D, Chen P-S, Chen H-SV, Quertermous T, Chang C-P (2014) A long noncoding RNA protects the heart from pathological hypertrophy. *Nature* 514: 102–106
- Han X, Yang F, Cao H, Liang Z (2015) Malat1 regulates serum response factor through miR-133 as a competing endogenous RNA in myogenesis. *FASEB J* 29: 3054–3064
- Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S, Barnes I, Bignell A, Boychenko V, Hunt T, Kay M, Mukherjee G, Rajan J, Despacio-Reyes G, Saunders G, Steward C et al (2012) GENCODE: the reference human genome annotation for The ENCODE Project. *Genome Res* 22: 1760–1774
- Harvey PA, Leinwand LA (2011) The cell biology of disease: cellular mechanisms of cardiomyopathy. *J Cell Biol* 194: 355–365
- Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK (2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* 38: 576–589
- Kaffer CR, Grinberg A, Pfeifer K (2001) Regulatory mechanisms at the mouse Igf2/H19 locus. *Mol Cell Biol* 21: 8189–8196
- Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL (2013) TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol* 14: R36
- Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9: 357–359
- Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, Fatica A, Santini T, Andronache A, Wade M, Laneve P, Rajewsky N, Bozzoni I (2017) Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. *Mol Cell* 66: 22–37.e9
- Levitt N, Briggs D, Gil A, Proudfoot NJ (1989) Definition of an efficient synthetic poly(A) site. *Genes Dev* 3: 1019–1025
- MacQuarrie KL, Yao Z, Fong AP, Diede SJ, Rudzinski ER, Hawkins DS, Tapscott SJ (2013) Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors. *Mol Cell Biol* 33: 773–784

- Maron BJ, Maron MS, Semsarian C (2012) Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. *J Am Coll Cardiol* 60: 705–715
- Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnetjournal* 17: 10–12
- Morlando M, Ballarino M, Fatica A, Bozzoni I (2014) The role of long noncoding RNAs in the epigenetic control of gene expression. *ChemMedChem* 9: 505–510
- Mousavi K, Zare H, Koulis M, Sartorelli V (2014) The emerging roles of eRNAs in transcriptional regulatory networks. *RNA Biol* 11: 106–110
- Mueller AC, Cichewicz MA, Dey BK, Lauer R, Reon BJ, Gagan JR, Dutta A (2015) MUNC, a long noncoding RNA that facilitates the function of MyoD in skeletal myogenesis. *Mol Cell Biol* 35: 498–513
- Mula J, Lee JD, Liu F, Yang L, Peterson CA (2013) Automated image analysis of skeletal muscle fiber cross-sectional area. *J Appl Physiol* 114: 148–155
- Nelson BR, Makarewich CA, Anderson DM, Winders BR, Troupes CD, Wu F, Reese AL, McAnally JR, Chen X, Kavalali ET, Cannon SC, Houser SR, Bassel-Duby R, Olson EN (2016) A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. *Science* 351: 271–275
- Noguchi S, Arakawa T, Fukuda S, Furuno M, Hasegawa A, Hori F, Ishikawa-Kato S, Kaida K, Kaiho A, Kanamori-Katayama M, Kawashima T, Kojima M, Kubosaki A, Manabe R-I, Murata M, Nagao-Sato S, Nakazato K, Ninomiya N, Nishiyori-Sueki H, Noma S et al (2017) FANTOM5 CAGE profiles of human and mouse samples. *Sci Data* 4: 170112
- Onzain S, Micheletti R, Arnan C, Plaisance I, Cecchi D, Schroen B, Reverter F, Alexanian M, Gonzales C, Ng SY, Bussotti G, Pezzuto I, Notredame C, Heymans S, Guigó R, Johnson R, Pedrazzini T (2015) CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. *J Mol Cell Cardiol* 89: 98–112
- Onzain S, Pedrazzini T (2015) The promise of enhancer-associated long noncoding RNAs in cardiac regeneration. *Trends Cardiovasc Med* 25: 592–602
- Pang KC, Frith MC, Mattick JS (2006) Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. *Trends Genet* 22: 1–5
- Patel RK, Jain M (2012) NGS QC toolkit: a toolkit for quality control of next generation sequencing data. *PLoS One* 7: e30619
- Quinlan AR, Hall IM (2010) BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* 26: 841–842
- Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A, Tyagi S (2008) Imaging individual mRNA molecules using multiple singly labeled probes. *Nat Methods* 5: 877–879
- Ribeiro DM, Zanzoni A, Cipriano A, Delli Ponti R, Spinelli L, Ballarino M, Bozzoni I, Tartaglia GG, Brun C (2017) Protein complex scaffolding predicted as a prevalent function of long non-coding RNAs. *Nucleic Acids Res* 46: 917–928
- Rinn JL, Chang HY (2012) Genome regulation by long noncoding RNAs. *Annu Rev Biochem* 81: 145–166
- Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP (2011) Integrative genomics viewer. *Nat Biotechnol* 29: 24–26
- Rowley MJ, Corces VG (2016) The three-dimensional genome: principles and roles of long-distance interactions. *Curr Opin Cell Biol* 40: 8–14
- Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell* 146: 353–358
- Schober H, Kalck V, Vega-Palas MA, Van Houwe G, Sage D, Unser M, Gartenberg MR, Gasser SM (2008) Controlled exchange of chromosomal arms reveals principles driving telomere interactions in yeast. *Genome Res* 18: 261–271
- Severin J, Lizio M, Harshbarger J, Kawaji H, Daub CO, Hayashizaki Y; FANTOM Consortium, Bertin N, Forrest AR (2014) Interactive visualization and analysis of large-scale sequencing datasets using ZENBU. *Nat Biotechnol* 32: 217–219
- Thorvaldsdóttir H, Robinson JT, Mesirov JP (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform* 14: 178–192
- Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L (2012) Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* 7: 562–578
- Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L (2013) Differential analysis of gene regulation at transcript resolution with RNA-seq. *Nat Biotechnol* 31: 46–53
- Tsai M-C, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, Chang HY (2010) Long noncoding RNA as modular scaffold of histone modification complexes. *Science* 329: 689–693
- Uchida S, Dimmeler S (2015) Long noncoding RNAs in cardiovascular diseases. *Circ Res* 116: 737–750
- Wang J, Gong C, Maquat LE (2013) Control of myogenesis by rodent SINE-containing lncRNAs. *Genes Dev* 27: 793–804
- Wang L, Zhao Y, Bao X, Zhu X, Kwok YK-Y, Sun K, Chen X, Huang Y, Jauch R, Esteban MA, Sun H, Wang H (2015) lncRNA Dum interacts with Dnmts to regulate Dppa2 expression during myogenic differentiation and muscle regeneration. *Cell Res* 25: 335–350
- Wang Z, Zhang X-J, Ji Y-X, Zhang P, Deng K-Q, Gong J, Ren S, Wang X, Chen I, Wang H, Gao C, Yokota T, Ang YS, Li S, Cass A, Vondriska TM, Li G, Deb A, Srivastava D, Yang H-T et al (2016) The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. *Nat Med* 22: 1131–1139
- Wutz A, Rasmussen TP, Jaenisch R (2002) Chromosomal silencing and localization are mediated by different domains of Xist RNA. *Nat Genet* 30: 167–174
- Yang H, Wang H, Jaenisch R (2014) Generating genetically modified mice using CRISPR/Cas-mediated genome engineering. *Nat Protoc* 9: 1956–1968
- Yonaha M, Proudfoot NJ (2000) Transcriptional termination and coupled polyadenylation *in vitro*. *EMBO J* 19: 3770–3777
- Zaug AJ, Cech TR (1980) *In vitro* splicing of the ribosomal RNA precursor in nuclei of tetrahymena. *Cell* 19: 331–338
- Zhang Y, Liu T, Meyer CA, Eickhout J, Johnson DS, Bernstein BE, Nussbaum C, Myers RM, Brown M, Li W, Liu XS (2008) Model-based analysis of ChIP-Seq (MACS). *Genome Biol* 9: R137



**License:** This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.